REFERENCES
1. Malik B, Feng FY. Long noncoding RNAs in prostate cancer: overview and clinical implications. Asian J Androl 2016;18:568-74.
2. Shi T, Gao G, Cao Y. Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. Dis Markers 2016;2016:9085195.
3. Jiang X, Yan Y, Hu M, et al. Increased level of H19 long noncoding RNA promotes invasion, angiogenesis, and stemness of glioblastoma cells. J Neurosurg 2016;124:129-36.
6. Xi J, Sun Q, Ma L, Kang J. Long non-coding RNAs in glioma progression. Cancer Lett 2018;419:203-9.
7. Yang M, Zhai Z, Guo S, Li X, Zhu Y, Wang Y. Long non-coding RNA FLJ33360 participates in ovarian cancer progression by sponging miR-30b-3p. Onco Targets Ther 2019;12:4469-80.
8. Shao M, Liu W, Wang Y. Differentially expressed LncRNAs as potential prognostic biomarkers for glioblastoma. Cancer Genet 2018;226-7:23-9.
9. Kiang KMY, Leung GKK. Clinical significance of CRNDE transcript variants in glioblastoma multiforme. Noncoding RNA Res 2017;2:119-21.
10. Ma Y, Luo T, Dong D, Wu X, Wang Y. Characterization of long non-coding RNAs to reveal potential prognostic biomarkers in hepatocellular carcinoma. Gene 2018;663:148-56.
11. Zeng T, Li L, Zhou Y, Gao L. Exploring long noncoding RNAs in glioblastoma: regulatory mechanisms and clinical potentials. Int J Genomics 2018;2018:2895958.
12. Balas MM, Johnson AM. Exploring the mechanisms behind long noncoding RNAs and cancer. Noncoding RNA Res 2018;3:108-17.
13. Cabili MN, Dunagin MC, McClanahan PD, et al. Localization and abundance analysis of human lncRNAs at single-cell and single-molecule resolution. Genome Biol 2015;16:20.
14. Duran R, Wei H, Kim DH, Wu JQ. Invited review: long non-coding RNAs: important regulators in the development, function and disorders of the central nervous system. Neuropathol Appl Neurobiol 2019;45:538-56.
15. Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol 2021;220:e202009045.
16. Clark MB, Johnston RL, Inostroza-Ponta M, et al. Genome-wide analysis of long noncoding RNA stability. Genome Res 2012;22:885-98.
17. Bresson SM, Hunter OV, Hunter AC, Conrad NK. Canonical Poly(A) polymerase activity promotes the decay of a wide variety of mammalian nuclear RNAs. PLoS Genet 2015;11:e1005610.
18. Du Z, Sun T, Hacisuleyman E, et al. Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer. Nat Commun 2016;7:10982.
19. Grelet S, Link LA, Howley B, et al. A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression. Nat Cell Biol 2017;19:1105-15.
20. Lin A, Li C, Xing Z, et al. The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol 2016;18:213-24.
21. Gong C, Maquat LE. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. Nature 2011;470:284-8.
22. Rackham O, Shearwood AM, Mercer TR, Davies SM, Mattick JS, Filipovska A. Long noncoding RNAs are generated from the mitochondrial genome and regulated by nuclear-encoded proteins. RNA 2011;17:2085-93.
23. Noh JH, Kim KM, Abdelmohsen K, et al. HuR and GRSF1 modulate the nuclear export and mitochondrial localization of the lncRNA RMRP. Genes Dev 2016;30:1224-39.
24. Kaewsapsak P, Shechner DM, Mallard W, Rinn JL, Ting AY. Live-cell mapping of organelle-associated RNAs via proximity biotinylation combined with protein-RNA crosslinking. Elife 2017;6:e29224.
25. Fazal FM, Han S, Parker KR, et al. Atlas of subcellular RNA localization revealed by APEX-Seq. Cell 2019;178:473-90.e26.
26. Jiang C, Li Y, Zhao Z, et al. Identifying and functionally characterizing tissue-specific and ubiquitously expressed human lncRNAs. Oncotarget 2016;7:7120-33.
27. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012;22:1775-89.
28. Washietl S, Kellis M, Garber M. Evolutionary dynamics and tissue specificity of human long noncoding RNAs in six mammals. Genome Res 2014;24:616-28.
30. Macrae TA, Fothergill-Robinson J, Ramalho-Santos M. Regulation, functions and transmission of bivalent chromatin during mammalian development. Nat Rev Mol Cell Biol 2023;24:6-26.
31. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006;125:315-26.
32. Beck D, Ben Maamar M, Skinner MK. Genome-wide CpG density and DNA methylation analysis method (MeDIP, RRBS, and WGBS) comparisons. Epigenetics 2022;17:518-30.
33. Elango N, Yi SV. DNA methylation and structural and functional bimodality of vertebrate promoters. Mol Biol Evol 2008;25:1602-8.
34. Song G, Shen Y, Zhu J, et al. Integrated analysis of dysregulated lncRNA expression in fetal cardiac tissues with ventricular septal defect. PLoS One 2013;8:e77492.
35. Wan G, Hu X, Liu Y, et al. A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO J 2013;32:2833-47.
36. Dinger ME, Amaral PP, Mercer TR, et al. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res 2008;18:1433-45.
37. Braconi C, Kogure T, Valeri N, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011;30:4750-6.
38. Wang J, Liu X, Wu H, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 2010;38:5366-83.
39. Shi X, Sun M, Wu Y, et al. Post-transcriptional regulation of long noncoding RNAs in cancer. Tumour Biol 2015;36:503-13.
40. Chiyomaru T, Fukuhara S, Saini S, et al. Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells. J Biol Chem 2014;289:12550-65.
41. Yoon JH, Abdelmohsen K, Kim J, et al. Scaffold function of long non-coding RNA HOTAIR in protein ubiquitination. Nat Commun 2013;4:2939.
42. Han Y, Liu Y, Zhang H, et al. Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long noncoding RNA MALAT1. FEBS Lett 2013;587:3875-82.
43. Wilusz JE, JnBaptiste CK, Lu LY, Kuhn CD, Joshua-Tor L, Sharp PA. A triple helix stabilizes the 3' ends of long noncoding RNAs that lack poly(A) tails. Genes Dev 2012;26:2392-407.
44. Brown JA, Valenstein ML, Yario TA, Tycowski KT, Steitz JA. Formation of triple-helical structures by the 3'-end sequences of MALAT1 and MENβ noncoding RNAs. Proc Natl Acad Sci USA 2012;109:19202-7.
45. Cantara WA, Crain PF, Rozenski J, et al. The RNA Modification Database, RNAMDB: 2011 update. Nucleic Acids Res 2011;39:D195-201.
46. Yang Y, Zhou X, Jin Y. ADAR-mediated RNA editing in non-coding RNA sequences. Sci China Life Sci 2013;56:944-52.
48. Yang Y, Ye Y, Su X, He J, Bai W, He X. MSCs-derived exosomes and neuroinflammation, neurogenesis and therapy of traumatic brain injury. Front Cell Neurosci 2017;11:55.
49. Kim DK, Nishida H, An SY, Shetty AK, Bartosh TJ, Prockop DJ. Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI. Proc Natl Acad Sci USA 2016;113:170-5.
50. Shi Y, Shi H, Nomi A, Lei-Lei Z, Zhang B, Qian H. Mesenchymal stem cell-derived extracellular vesicles: a new impetus of promoting angiogenesis in tissue regeneration. Cytotherapy 2019;21:497-508.
51. Roura S, Monguió-Tortajada M, Munizaga-Larroudé M, et al. Potential of extracellular vesicle-associated TSG-6 from adipose mesenchymal stromal cells in traumatic brain injury. Int J Mol Sci 2020;21:6761.
52. Wang CF, Zhao CC, Weng WJ, et al. Alteration in long non-coding RNA expression after traumatic brain injury in rats. J Neurotrauma 2017;34:2100-8.
53. Zhong J, Jiang L, Cheng C, et al. Altered expression of long non-coding RNA and mRNA in mouse cortex after traumatic brain injury. Brain Res 2016;1646:589-600.
54. Yang LX, Yang LK, Zhu J, Chen JH, Wang YH, Xiong K. Expression signatures of long non-coding RNA and mRNA in human traumatic brain injury. Neural Regen Res 2019;14:632-41.
55. Shen H, Fan C, You Z, Xiao Z, Zhao Y, Dai J. Advances in biomaterial-based spinal cord injury repair. Adv Funct Mater 2022;32:2110628.
56. Badhiwala JH, Wilson JR, Fehlings MG. Global burden of traumatic brain and spinal cord injury. Lancet Neurol 2019;18:24-5.
57. Hatch BB, Wood-Wentz CM, Therneau TM, Walker MG, Payne JM, Reeves RK. Factors predictive of survival and estimated years of life lost in the decade following nontraumatic and traumatic spinal cord injury. Spinal Cord 2017;55:540-4.
58. Ramer LM, Ramer MS, Bradbury EJ. Restoring function after spinal cord injury: towards clinical translation of experimental strategies. Lancet Neurol 2014;13:1241-56.
59. Wang J, Hu B, Cao F, Sun S, Zhang Y, Zhu Q. Down regulation of lncSCIR1 after spinal cord contusion injury in rat. Brain Res 2015;1624:314-20.
60. Zhou H, Shi Z, Kang Y, et al. Investigation of candidate long noncoding RNAs and messenger RNAs in the immediate phase of spinal cord injury based on gene expression profiles. Gene 2018;661:119-25.
61. Wang W, Su Y, Tang S, et al. Identification of noncoding RNA expression profiles and regulatory interaction networks following traumatic spinal cord injury by sequence analysis. Aging 2019;11:2352-68.
62. Moonga J, Likupe G. A systematic literature review on nurses’ and health care support workers’ experiences of caring for people with dementia on orthopaedic wards. J Clin Nurs 2016;25:1789-804.
63. Näslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000;283:1571-7.
64. Vassar R, Kandalepas PC. The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. Alzheimers Res Ther 2011;3:20.
65. Riva P, Ratti A, Venturin M. The long non-coding RNAs in neurodegenerative diseases: novel mechanisms of pathogenesis. Curr Alzheimer Res 2016;13:1219-31.
66. Airavaara M, Pletnikova O, Doyle ME, Zhang YE, Troncoso JC, Liu QR. Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease. J Biol Chem 2011;286:45093-102.
67. Massone S, Vassallo I, Fiorino G, et al. 17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease. Neurobiol Dis 2011;41:308-17.
68. Parenti R, Paratore S, Torrisi A, Cavallaro S. A natural antisense transcript against Rad18, specifically expressed in neurons and upregulated during beta-amyloid-induced apoptosis. Eur J Neurosci 2007;26:2444-57.
69. Mus E, Hof PR, Tiedge H. Dendritic BC200 RNA in aging and in Alzheimer's disease. Proc Natl Acad Sci USA 2007;104:10679-84.
70. Ciarlo E, Massone S, Penna I, et al. An intronic ncRNA-dependent regulation of SORL1 expression affecting Aβ formation is upregulated in post-mortem Alzheimer's disease brain samples. Dis Model Mech 2013;6:424-33.
71. Massone S, Ciarlo E, Vella S, et al. NDM29, a RNA polymerase III-dependent non coding RNA, promotes amyloidogenic processing of APP and amyloid β secretion. Biochim Biophys Acta 2012;1823:1170-7.
72. Gu C, Chen C, Wu R, et al. Long noncoding RNA EBF3-AS promotes neuron apoptosis in Alzheimer's disease. DNA Cell Biol 2018;37:220-6.
73. Ferreira JJ, Rodrigues FB, Duarte GS, et al. An MDS evidence-based review on treatments for Huntington's disease. Mov Disord 2022;37:25-35.
74. Lee M, Liu T, Im W, Kim M. Exosomes from adipose-derived stem cells ameliorate phenotype of Huntington's disease in vitro model. Eur J Neurosci 2016;44:2114-9.
76. Chung DW, Rudnicki DD, Yu L, Margolis RL. A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum Mol Genet 2011;20:3467-77.
77. Sunwoo JS, Lee ST, Im W, et al. Altered expression of the long noncoding RNA NEAT1 in Huntington's disease. Mol Neurobiol 2017;54:1577-86.
78. Koistinen H, Kovanen RM, Hollenberg MD, et al. The roles of proteases in prostate cancer. IUBMB Life 2023;75:493-513.
79. Chakravarty D, Sboner A, Nair SS, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun 2014;5:5383.
80. Yuan S, Bi J, Zhang Y. LncRNA SSTR5-AS1 as a prognostic marker promotes cell proliferation and epithelial-to-mesenchymal transition in prostate cancer. Crit Rev Eukaryot Gene Expr 2023;33:1-12.
81. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33.
82. Sideris N, Dama P, Bayraktar S, Stiff T, Castellano L. LncRNAs in breast cancer: a link to future approaches. Cancer Gene Ther 2022;29:1866-77.
83. Sang Y, Tang J, Li S, et al. LncRNA PANDAR regulates the G1/S transition of breast cancer cells by suppressing p16(INK4A) expression. Sci Rep 2016;6:22366.
84. Zhang J, Sui S, Wu H, et al. The transcriptional landscape of lncRNAs reveals the oncogenic function of LINC00511 in ER-negative breast cancer. Cell Death Dis 2019;10:599.
85. Li H, Chen C, Fan J, et al. Identification of cardiac long non-coding RNA profile in human dilated cardiomyopathy. Cardiovasc Res 2018;114:747-58.
86. Zhang X, Yuan S, Liu J, et al. Overexpression of cytosolic long noncoding RNA cytb protects against pressure-overload-induced heart failure via sponging microRNA-103-3p. Mol Ther Nucleic Acids 2022;27:1127-45.
87. Xie R, Fan J, Wen J, et al. LncRNA ZNF593-AS alleviates diabetic cardiomyopathy via suppressing IRF3 signaling pathway. Mol Ther Nucleic Acids 2023;32:689-703.
88. Fan J, Li H, Xie R, et al. LncRNA ZNF593-AS alleviates contractile dysfunction in dilated cardiomyopathy. Circ Res 2021;128:1708-23.
89. Zhong J, Jiang L, Huang Z, et al. The long non-coding RNA Neat1 is an important mediator of the therapeutic effect of bexarotene on traumatic brain injury in mice. Brain Behav Immun 2017;65:183-94.
90. Patel NA, Moss LD, Lee JY, et al. Long noncoding RNA MALAT1 in exosomes drives regenerative function and modulates inflammation-linked networks following traumatic brain injury. J Neuroinflamm 2018;15:204.
91. Harris L, Zalucki O, Piper M, Heng JI. Insights into the biology and therapeutic applications of neural stem cells. Stem Cells Int 2016;2016:9745315.
92. Zheng J, Yi D, Liu Y, Wang M, Zhu Y, Shi H. Long nonding RNA UCA1 regulates neural stem cell differentiation by controlling miR-1/Hes1 expression. Am J Transl Res 2017;9:3696-704. Available from: https://europepmc.org/article/MED/28861160 [Last accessed on 1 Apr 2024].
93. Liu Y, Pan L, Jiang A, Yin M. Hydrogen sulfide upregulated lncRNA CasC7 to reduce neuronal cell apoptosis in spinal cord ischemia-reperfusion injury rat. Biomed Pharmacother 2018;98:856-62.
94. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 2003;67:657-85.
95. Faghihi MA, Modarresi F, Khalil AM, et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med 2008;14:723-30.
96. Johnson R. Long non-coding RNAs in Huntington's disease neurodegeneration. Neurobiol Dis 2012;46:245-54.
97. Ksiazek-Winiarek DJ, Szpakowski P, Glabinski A. Neural plasticity in multiple sclerosis: the functional and molecular background. Neural Plast 2015;2015:307175.
98. Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 2004;24:4250-8.
99. Zuccato C, Tartari M, Crotti A, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003;35:76-83.
100. Ghafouri-Fard S, Khoshbakht T, Taheri M, Ghanbari M. A concise review on the role of BDNF-AS in human disorders. Biomed Pharmacother 2021;142:112051.
101. Yin X, Wang S, Ge R, et al. Long non-coding RNA DNMBP-AS1 promotes prostate cancer development by regulating LCLAT1. Syst Biol Reprod Med 2023;69:142-52.
102. Zhang W, Shi C, Xu Q, Chen X, Zhu H, Zheng B. Long non-coding RNA MIR22HG suppresses cell proliferation and promotes apoptosis in prostate cancer cells by sponging microRNA-9-3p. Bioengineered 2022;13:13108-17.
103. Ren Y, Jia HH, Xu YQ, et al. Paracrine and epigenetic control of CAF-induced metastasis: the role of HOTAIR stimulated by TGF-ß1 secretion. Mol Cancer 2018;17:5.
104. Khorkova O, Wahlestedt C. Oligonucleotide therapies for disorders of the nervous system. Nat Biotechnol 2017;35:249-63.
105. Zhu Y, Zhu L, Wang X, Jin H. RNA-based therapeutics: an overview and prospectus. Cell Death Dis 2022;13:644.
106. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov 2021;20:629-51.
107. Chi X, Gatti P, Papoian T. Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov Today 2017;22:823-33.
108. Migliorati JM, Liu S, Liu A, et al. Absorption, distribution, metabolism, and excretion of US food and drug administration-approved antisense oligonucleotide drugs. Drug Metab Dispos 2022;50:888-97.
109. Germain ND, Chung WK, Sarmiere PD. RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases. Mol Aspects Med 2023;91:101148.
110. Sheng P, Flood KA, Xie M. Short hairpin RNAs for strand-specific small interfering RNA production. Front Bioeng Biotechnol 2020;8:940.
111. Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med 2014;6:851-64.
112. Lima JF, Cerqueira L, Figueiredo C, Oliveira C, Azevedo NF. Anti-miRNA oligonucleotides: a comprehensive guide for design. RNA Biol 2018;15:338-52.
113. Kluiver J, Slezak-Prochazka I, Smigielska-Czepiel K, Halsema N, Kroesen BJ, van den Berg A. Generation of miRNA sponge constructs. Methods 2012;58:113-7.
114. Chang S. Construction of multi-potent microRNA sponge and its functional evaluation. In: Wu W, editor. MicroRNA and cancer. New York: Springer; 2018. pp. 201-9.
115. Jung J, Yeom C, Choi YS, et al. Simultaneous inhibition of multiple oncogenic miRNAs by a multi-potent microRNA sponge. Oncotarget 2015;6:20370-87.
116. Das S, Kohr M, Dunkerly-Eyring B, et al. Divergent effects of miR-181 family members on myocardial function through protective cytosolic and detrimental mitochondrial microRNA targets. J Am Heart Assoc 2017;6:e004694.
117. Wang Z. The Principles of MiRNA-masking antisense oligonucleotides technology. In: Wu W, editor. MicroRNA and cancer. Totowa: Humana Press; 2011. pp. 43-9.
118. Gilot D, Migault M, Bachelot L, et al. A non-coding function of TYRP1 mRNA promotes melanoma growth. Nat Cell Biol 2017;19:1348-57.
119. Almarghalani DA, Boddu SHS, Ali M, et al. Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and progress in drug delivery systems. Neural Regen Res 2022;17:1717-25.
120. Friedrich M, Aigner A. Therapeutic siRNA: state-of-the-art and future perspectives. BioDrugs 2022;36:549-71.
121. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol 2021;22:96-118.
122. Modarresi F, Faghihi MA, Lopez-Toledano MA, et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol 2012;30:453-9.
123. Lee D, Chen W, Kaku HN, et al. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome. Elife 2023;12:e81892.
124. de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm 1999;7:189-98.
125. Parham JS, Goldberg AC. Mipomersen and its use in familial hypercholesterolemia. Expert Opin Pharmaco 2019;20:127-31.
127. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res 2014;42:609-21.
128. Gallant-Behm CL, Piper J, Lynch JM, et al. A MicroRNA-29 mimic (Remlarsen) represses extracellular matrix expression and fibroplasia in the skin. J Invest Dermatol 2019;139:1073-81.
129. Regulus Therapeutics I. RG-125 (AZD4076), a microRNA therapeutic targeting microRNA-103/107 for the treatment of NASH in patients with type 2 diabetes/pre-diabetes, selected as clinical candidate by AstraZeneca. 2015. Available from: https://www.prnewswire.com/news-releases/rg-125-azd4076-a-microrna-therapeutic-targeting-microrna-103107-for-the-treatment-of-nash-in-patients-with-type-2-diabetespre-diabetes-selected-as-clinical-candidate-by-astrazeneca-300062261.html [Last accessed on 1 Apr 2024].
131. Siddiqui MA, Keating GM. Pegaptanib: in exudative age-related macular degeneration. Drugs 2005;65:1571-7; discussion 1578-9.
132. Goodkey K, Aslesh T, Maruyama R, Yokota T. Nusinersen in the treatment of spinal muscular atrophy. In: Yokota T, Maruyama R, editors. Exon skipping and inclusion therapies. New York: Springer; 2018. pp. 69-76.
135. Bravo-Hernandez M, Tadokoro T, Navarro MR, et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat Med 2020;26:118-30.
136. Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med 2018;24:257-77.
138. Lennox KA, Behlke MA. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res 2016;44:863-77.
139. Gagnon KT, Li L, Chu Y, Janowski BA, Corey DR. RNAi factors are present and active in human cell nuclei. Cell Rep 2014;6:211-21.
140. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011;30:16-34.
141. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses. Eur J Immunol 2006;36:1222-30.
143. Hong DS, Kang YK, Borad M, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer 2020;122:1630-7.
144. Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs 2017;35:180-8.
145. Pisano M, Baldinu P, Sini MC, Ascierto PA, Tanda F, Palmieri G. Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. Ann Oncol 2008;19:2092-3.
146. Anderson EM, Miller P, Ilsley D, et al. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Cancer Gene Ther 2006;13:406-14.
147. Winkler J, Stessl M, Amartey J, Noe CR. Off-target effects related to the phosphorothioate modification of nucleic acids. ChemMedChem 2010;5:1344-52.
148. Wen J, Friedman JR. miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest 2012;122:2773-6.
149. Ui-Tei K, Naito Y, Nishi K, Juni A, Saigo K. Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect. Nucleic Acids Res 2008;36:7100-9.
150. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-41.
151. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 2009;27:549-55.
152. Hart M, Nickl L, Walch-Rueckheim B, et al. Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4+, CD8+ T cells, and M1 macrophages. J Immunother Cancer 2020;8:e001617.
153. LaCasse EC. Pulling the plug on a cancer cell by eliminating XIAP with AEG35156. Cancer Lett 2013;332:215-24.
154. Fazaeli H, Sheikholeslami A, Ghasemian F, Amini E, Sheykhhasan M. The emerging role of LncRNA FENDRR in multiple cancers: a review. Curr Mol Med 2023;23:606-29.
155. da Silva AMG, Cruz MS, de Souza KSC, Silbiger VN. Long non-coding RNA and circular RNA: new perspectives for molecular pathophysiology of atrial fibrillation. Mol Biol Rep 2023;50:2835-45.
156. Loganathan T, Doss C GP. Non-coding RNAs in human health and disease: potential function as biomarkers and therapeutic targets. Funct Integr Genomics 2023;23:33.
157. Jiapaer Z, Li C, Yang X, et al. Extracellular non-coding RNAs in cardiovascular diseases. Pharmaceutics 2023;15:155.
158. Dong B, Zhang F, Zhang W, Gao Y. IncRNA EPB41L4A-AS1 mitigates the proliferation of non-small-cell lung cancer cells through the miR-105-5p/GIMAP6 axis. Crit Rev Eukaryot Gene Expr 2023;33:27-40.
